Noel Ripberger-Scheick

Cooley advised Delphix, a vendor of test data management software, on its acquisition by Perforce, a provider of solutions to enterprise teams requiring productivity, visibility and scale along the development life cycle.

Cooley advised Ramp, a finance automation platform, on its $300 million Series D financing.

Cooley advised Freshworks, a leading software company empowering businesses to delight their customers and employees, on its $1.1286 billion initial public offering of shares of Class A common stock. Lawyers Jon Avina, Dave Segre, Calise Cheng and Sepideh Mousakhani led the Cooley team advising Freshworks.

Cooley advised NeuroPace on its $117.3 million initial public offering of 6,900,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. NeuroPace, whose securities now trade on the Nasdaq Global Market under the symbol NPCE, is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy. Partners Mark Weeks and Seth Gottlieb led the Cooley team.

Cooley advised Landos Biopharma on its $100 million initial public offering of 6,250,000 shares of common stock. Landos Biopharma, whose securities now trade on the Nasdaq Global Select Market under the symbol LABP, is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases. Partners Eric Blanchard, Madison Jones and Div Gupta led the Cooley team.